Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractIntroductionAlthough daratumumab‐containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable.Methods and ObjectiveWe performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark the efficacy of carfilzomib‐ or pomalidomide‐based therapies immediately following progression on daratumumab treatment.ResultsWe identified 178 such patients; median number of prior lines of therapy was 3, 97% triple‐class exposed, and 60% triple‐class refractory. In our cohort, 75 received a subsequent carfilzomib‐based therapy, 79 received a pomalidomide‐based therapy, and 24 received a treatment with both immunomodulatory drug (IMiD) and proteasome inhibitor (PI) using carfilzomib and/or pomalidomide. The median progression‐free survival (PFS) and overall survival (OS) for the entire cohort were 4.5 and 14.2 months, respectively. Carfilzomib‐based therapy yielded a median PFS and OS of 4.5 and 10.2 months, respectively, compared to 5.2 and 21.7 months for pomalidomide‐based therapy. Patients who received both IMiD and PI with carfilzomib and/or pomalidomide had a median PFS and OS of 4.1 and 14.5 months, respectively.ConclusionOur observations demonstrate the poor outcome of MM patients when standard regimens based on carfilzomib and/or pomalidomide are utilized directly after daratumumab‐based therapy given in the relapsed setting. Novel therapies, including immune therapies, are urgently needed to improve the outcomes of these daratumumab‐exposed patients.
